Prachi Bhatt

For ACOs, the implications of the Medicare GLP-1 Bridge program extends beyond access to include medication adherence and chronic care management.

Multiple sclerosis costs employers nationwide more than $1 billion annually, but we estimate there is an opportunity to reduce disability-related claim costs by up to 30%.

With the 2026 implementation of maximum fair prices on selected anticoagulants, we modeled potential effects on rates of treatment for Medicare Part D beneficiaries.

CMS’s Cell and Gene Therapy Access Model offers Medicaid programs increased access to the treatment while addressing complexities and financial uncertainties.